Latest Insider Transactions at Crinetics Pharmaceuticals, Inc. (CRNX)
This section provides a real-time view of insider transactions for Crinetics Pharmaceuticals, Inc. (CRNX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Crinetics Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Crinetics Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2022
|
Ajay Madan Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,950
+6.98%
|
-
|
|
Feb 28
2022
|
Marc Wilson CFO |
BUY
Grant, award, or other acquisition
|
Direct |
19,500
+19.28%
|
-
|
|
Feb 28
2022
|
Jeff E. Knight Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,950
+50.0%
|
-
|
|
Feb 28
2022
|
Richard Scott Struthers President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
53,400
+48.19%
|
-
|
|
Feb 15
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,123
-2.46%
|
$56,214
$18.64 P/Share
|
|
Feb 07
2022
|
Ajay Madan Chief Development Officer |
SELL
Open market or private sale
|
Direct |
13,411
-7.23%
|
$227,987
$17.83 P/Share
|
|
Feb 01
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,123
-2.41%
|
$56,214
$18.79 P/Share
|
|
Jan 19
2022
|
Alan Seth Krasner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,700
-44.63%
|
$140,700
$21.21 P/Share
|
|
Jan 19
2022
|
Alan Seth Krasner Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,700
+30.86%
|
$80,400
$12.01 P/Share
|
|
Jan 18
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,168
-3.13%
|
$95,864
$23.29 P/Share
|
|
Jan 03
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,168
-5.11%
|
$200,704
$28.02 P/Share
|
|
Dec 28
2021
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-2.09%
|
$81,000
$27.95 P/Share
|
|
Dec 15
2021
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,668
-3.81%
|
$136,032
$24.14 P/Share
|
|
Dec 01
2021
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,668
-3.67%
|
$153,036
$27.38 P/Share
|
|
Nov 16
2021
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,500
-0.96%
|
$40,500
$27.97 P/Share
|
|
Nov 15
2021
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,668
-3.5%
|
$147,368
$26.75 P/Share
|
|
Nov 08
2021
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,900
-2.35%
|
$109,200
$28.42 P/Share
|
|
Nov 05
2021
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,600
-7.07%
|
$340,200
$27.95 P/Share
|
|
Nov 01
2021
|
Matthew K Fust |
SELL
Open market or private sale
|
Direct |
8,954
-41.67%
|
$223,850
$25.5 P/Share
|
|
Nov 01
2021
|
Matthew K Fust |
BUY
Exercise of conversion of derivative security
|
Direct |
8,954
+29.41%
|
$8,954
$1.91 P/Share
|
|
Nov 01
2021
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,668
-3.08%
|
$136,032
$24.79 P/Share
|
|
Oct 28
2021
|
Ajay Madan Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
106,383
+36.55%
|
$0
$0.73 P/Share
|
|
Oct 27
2021
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-1.61%
|
$72,000
$24.0 P/Share
|
|
Oct 25
2021
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,200,000
+18.86%
|
$22,800,000
$19.8 P/Share
|
|
Oct 21
2021
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,042
-0.55%
|
$21,882
$21.1 P/Share
|
|
Sep 08
2021
|
Matthew K Fust |
SELL
Open market or private sale
|
Direct |
6,046
-32.54%
|
$151,150
$25.5 P/Share
|
|
Sep 08
2021
|
Matthew K Fust |
BUY
Exercise of conversion of derivative security
|
Direct |
6,046
+24.55%
|
$6,046
$1.91 P/Share
|
|
Sep 07
2021
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Indirect |
30,000
-10.0%
|
$750,000
$25.0 P/Share
|
|
Jul 26
2021
|
Matthew K Fust |
SELL
Open market or private sale
|
Direct |
5,000
-28.51%
|
$95,000
$19.59 P/Share
|
|
Jul 26
2021
|
Matthew K Fust |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+22.19%
|
$5,000
$1.91 P/Share
|
|
Jul 19
2021
|
Matthew K Fust |
SELL
Open market or private sale
|
Direct |
5,000
-28.51%
|
$95,000
$19.5 P/Share
|
|
Jul 19
2021
|
Matthew K Fust |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+22.19%
|
$5,000
$1.91 P/Share
|
|
Jul 12
2021
|
Matthew K Fust |
SELL
Open market or private sale
|
Direct |
5,000
-28.51%
|
$100,000
$20.71 P/Share
|
|
Jul 12
2021
|
Matthew K Fust |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+22.19%
|
$5,000
$1.91 P/Share
|
|
Apr 08
2021
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
304,136
+7.13%
|
$4,866,176
$16.44 P/Share
|
|
Dec 03
2020
|
Richard Scott Struthers President & CEO |
BUY
Open market or private purchase
|
Direct |
4,000
+50.0%
|
$52,000
$13.1 P/Share
|
|
Dec 02
2020
|
Richard Scott Struthers President & CEO |
BUY
Open market or private purchase
|
Indirect |
1,000
+50.0%
|
$12,000
$12.6 P/Share
|
|
Jul 16
2020
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Indirect |
17,500
-1.93%
|
$245,000
$14.46 P/Share
|
|
Jul 15
2020
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Indirect |
17,500
-1.89%
|
$262,500
$15.3 P/Share
|
|
Apr 28
2020
|
Wendall Wierenga |
BUY
Exercise of conversion of derivative security
|
Direct |
25,329
+20.23%
|
$0
$0.73 P/Share
|
|
Apr 17
2020
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,071,428
+22.65%
|
$14,999,992
$14.0 P/Share
|
|
Apr 17
2020
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
84,598
-3.32%
|
$1,268,970
$15.4 P/Share
|
|
Apr 16
2020
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
30,190
-1.17%
|
$452,850
$15.2 P/Share
|
|
Apr 15
2020
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
215,810
-7.73%
|
$3,237,150
$15.5 P/Share
|
|
Apr 07
2020
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
6,115
-0.22%
|
$85,610
$14.2 P/Share
|
|
Apr 03
2020
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
300,000
-9.68%
|
$3,900,000
$13.8 P/Share
|
|
Mar 09
2020
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
528
-0.03%
|
$10,032
$19.5 P/Share
|
|
Feb 10
2020
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
7,555
-1.17%
|
$158,655
$21.4 P/Share
|
|
Feb 07
2020
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,905
-0.89%
|
$129,910
$22.0 P/Share
|
|
Feb 04
2020
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
13,460
-1.92%
|
$296,120
$22.8 P/Share
|